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DOI 10.1016/j.ccr.2011.12.025SUMMARYElevated Aurora kinase-A expression is correlated with abrogation of DNA damage-induced apoptotic
response and mitotic spindle assembly checkpoint (SAC) override in human tumor cells. We report that
Aurora-A phosphorylation of p73 at serine235 abrogates its transactivation function and causes cytoplasmic
sequestration in a complex with the chaperon protein mortalin. Aurora-A phosphorylated p73 also facilitates
inactivation of SAC through dissociation of the MAD2-CDC20 complex in cells undergoing mitosis. Cells
expressing phosphor-mimetic mutant (S235D) of p73 manifest altered growth properties, resistance to
cisplatin- induced apoptosis, as well as premature dissociation of the MAD2-CDC20 complex, and acceler-
ated mitotic exit with SAC override in the presence of spindle damage. Elevated cytoplasmic p73 in Aurora-A
overexpressing primary human tumors corroborates the experimental findings.INTRODUCTION G2/M progression, centrosome maturation-separation, bipolaAurora kinase-A (also called STK15/BTAK; hereinafter referred to
as Aurora-A), a key regulator of the mitotic cell division cycle, is
overexpressed in many human tumors and is associated with
abrogation of DNA damage-induced apoptotic response and
spindle assembly checkpoint (SAC) override in cancer cells.
Aurora-A, a cancer susceptibility gene (Ewart-Toland et al., 2003),
plays essential roles in the commitment of proliferating cells toSignificance
Resistance to DNA and spindle-damaging chemotherapeutic
tions in human cancer. Elevated Aurora kinase-A expression is
determinant of chemosensitivity in tumor cells. Our findings d
inactivation of its DNA damage and spindle assembly checkpo
chromatin-binding affinity, is sequestered in the cytoplasm,
assembly checkpoint complex. Elucidation of the molecular
DNA and spindle targeted therapeutic agents in Aurora-A ov
therapeutic regimens.
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spindle formation, and spindle damage recovery (Marumoto
et al., 2005; Katayama et al., 2008; Macurek et al., 2008; Seki
et al., 2008). We and others have previously identified functional
inactivation of p53 tumor suppressor protein after Aurora-A phos-
phorylation at serine 315and serine 215 residues; the former facil-
itates Mdm2-mediated degradation, and the latter causes loss of
DNA-binding ability in human cells (Katayama et al., 2004; Liu
et al., 2004). Aurora-A phosphorylation of BRCA1 at serine 308drugs is a major challenge to effective therapeutic interven-
correlated with chemotherapy resistance, and p73 is a major
emonstrate that p73 phosphorylation by Aurora-A results in
int response functions. Aurora-A-phosphorylated p73 loses
and facilitates dissociation of the MAD2-CDC20 spindle
mechanisms underlying the development of resistance to
erexpressing tumors should help us design more effective
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point (Ouchi et al., 2004). Furthermore, overexpression of Aurora-
A makes HeLa cells resistant to taxol-induced cell death due to
mitotic SAC override (Anand et al., 2003). A recent study found
that treatment of p53-deficient cells with Aurora-A small molecule
inhibitors activates p73 transactivation function with upregulation
of its downstream target genes during induction of cell death (Dar
et al., 2008). However, the molecular mechanisms underlying the
observed effects have not been elucidated.
The role of p73 in tumorigenesis has been debated because
loss of function mutations in the gene is rare. However, recently
developed transactivation-competent (TA) p73-specific gene-
knockout mice have a high incidence of spontaneous and
carcinogen-induced tumors (Tomasini et al., 2008). In addition,
oocytes and cells lacking TAp73 exhibit abnormal spindle struc-
ture and mitotic slippage with spindle poisons, indicating partic-
ipation of TAp73 in the SAC pathway (Tomasini et al., 2009).
More recent studies have demonstrated that TAp73 interacts
with SAC proteins Bub1, Bub3, and BubR1. TAp73-deficient or
knockdown cells reveal mislocalization of Bub1 and BubR1 at
the kinetochore and reduced BubR1 kinase activity, associated
with aneuploidy and chromosome instability (Tomasini et al.,
2009; Vernole et al., 2009). Together with proapoptotic function
of TAp73 in response to genotoxic stress, these results suggest
that p73 is directly involved in maintaining genomic stability and
regulating SAC pathway.
In view of Aurora-A overexpression reported to induce resis-
tance to DNA damage-mediated apoptosis response and SAC
override, we investigated the possible role of Aurora-A functional
interaction with p73 and the underlying molecular mechanisms
involved in the development of these phenotypes.
RESULTS
Aurora-A Phosphorylates p73
We hypothesized that direct phosphorylation of p73 by Aurora-A
negatively regulates p73 transactivation function and conse-
quential activation of apoptosis response. Because p73 is
reported to be phosphorylated in mitosis (Fulco et al., 2003),
we treated nocodazole- and taxol-arrested mitotic Cos-1 cells
with Aurora-A-specific inhibitor MLN8054 and proteasome
inhibitor MG132 to detect Aurora-A-specific posttranslational
p73 modification. p73 from inhibitor-treated mitotic cells
migrated faster than that from untreated cells, whereas p73
from exponentially growing cells had intermediate mobility (Fig-
ure 1A). The slower migrating form was seen in cells with active
Aurora-A, detected with anti-phospho T288 antibody. To deter-
mine whether slower mobility of p73 was due to phosphorylation
and whether Aurora-A is directly involved in p73 phosphoryla-
tion, we treated cell extracts with lPPase, with or without
Aurora-A inhibitor. While inhibitor treatment alone resulted in
minimal increase in mobility, lPPase treatment, both with or
without Aurora-A inhibitor, led to similar yet markedly faster
migration in p73. These results indicate that slower mobility
was due to multiple phosphorylations, possibly catalyzed by
several kinases, including Aurora-A. Aurora-A inhibition alone
resulted in aminor downward shift in gel mobility due to selective
interference with Aurora-A phosphorylation, but the more
rapidly migrating form was due to complete dephosphorylationCwith lPPase (Figure 1A). To determine direct involvement of
Aurora-A in p73 phosphorylation in vivo, we performed p73
immunoprecipitation, followed by immunoblotting with the
anti-phospho-PKA substrate antibody, which recognizes the
Aurora-A consensus phosphorylation motif in substrate proteins
(Katayama et al., 2007; Plotnikova et al., 2011). We observed
clear phosphor-PKA signal in immunoprecipitated p73 from
nocodazole-treated mitotic cells, which was diminished in inhib-
itor-treated samples. In exponentially growing cells, the phos-
phor-PKA signal changed little after treatment (Figure 1B). These
findings further verified the involvement of Aurora-A in p73 phos-
phorylation in vivo (Figures 1C and 1D).
We next performed an in vitro kinase assay of p73, with or
without wild-type (WT) or kinase-dead (KD) Aurora-A, with the
closely related paralog Aurora-B as a control. Aurora-A-WT phos-
phorylated p73, but Aurora-A-KD did not (Figure 1E). Complete
absence of phosphorylation signal on p73 with Aurora-B further
validated Aurora-A as the bona fide kinase of p73. We next iden-
tified the specific Aurora-A phosphorylated amino acid residue
in p73 using site-directed mutants in Aurora kinase consensus
phosphorylation motifs and subjecting them to in vitro kinase
assays. Theserine235alanine (S235A)mutant ofp73had reduced
phosphorylation than p73-WT, indicating that S235 is phosphory-
latedbyAurora-A (Figure1F).We furtherconfirmed thisphosphor-
ylation using an anti-phospho-PKA substrate-specific antibody.
p73-WT phosphorylation was evident in cells coexpressing
Aurora-A but not those expressing the empty vector. Phosphory-
lation was significantly diminished in cells expressing the S235A
mutant, demonstrating that serine 235 in p73 is phosphorylated
by Aurora-A (Figure 1G). It is intriguing that transactivation-defec-
tive DNp73 showed minimal loss of phosphorylation in the SA
mutant of the conserved motif and appeared to bind the WT and
the phosphor-mimetic (S235D) mutant of p73 with similar effi-
ciency (Figures S1A and S1B available online).
We determined in vivo interaction between Aurora-A and p73
by immunoprecipitation of 293T cells cotransfected with Flag-
Aurora-A and GFP-p73. Anti-Flag antibody revealed a specific
interaction between p73 and Aurora-A (Figure 1H). Anti-Flag
antibody immunoprecipitations also detected enriched pres-
ence of p73-S235D mutant in the immune complex compared
with S235A mutant (Figure S1C). To determine the interaction
between endogenous Aurora-A and p73, we used synchronized
mitotic cells for reciprocal immunoprecipitation experiments,
which revealed p73 andAurora-A in the same complex (Figure 1I)
that was absent in the p73 knockdown cells (Figure 1J). This
interaction was also detected in human nontumorigenic MCF-
10A mammary epithelial cells and p53-deficient H1299 lung
carcinoma cells (Figures S1D and S1E). Cell cycle dependence
of this interaction was analyzed in synchronized cells after
double thymidine block and release. Consistent with published
data (Fulco et al., 2003), p73 expression was uniform through
the cell cycle. The amount of Aurora-A bound to p73 progres-
sively increased, peaking at mitosis, which was also evident in
nocodazole-treated cells (Figure 1K).
Aurora-A Phosphorylated p73 Loses DNA Binding and
Transactivation Activity
Because the Aurora-A phosphorylation site is located in the
DNA-binding domain, we determined the effect of Aurora-Aancer Cell 21, 196–211, February 14, 2012 ª2012 Elsevier Inc. 197
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Figure 1. Aurora A Phosphorylates and Interacts with p73
(A) Cos-1 cells, grown with or without nocodazole or taxol for 20 hr, were cultured with or without Aurora-A inhibitor MLN8054 in the presence of MG132
for 4 hr. Whole cell extracts (WCE) were incubated with (+) or without () lPPase for 30 min. Samples were analyzed by immunoblotting with the indicated
antibodies.
(B) WCE prepared in (Figure 1A) were immunoprecipitated with anti-p73 antibody and subjected to immunoblotting with anti-pPKA substrate (top) and anti-p73
(bottom) antibodies. The pPKA signal was normalized by the amount of precipitated HA-p73, and the relative pPKA signal was quantified.
(C) HA-p73awas cotransfectedwith empty vector, Flag-WTAurora-A (WT), or Flag-KDAurora-A (KD) into Cos-1 cells. Twenty-four hours later, cells were cultured
with (+) or without () Aurora-A inhibitor for 4 hr. WCE were subjected to immunoblotting with anti-HA (top) and anti-Flag (bottom) antibodies.
(D) WCE prepared in (Figure 1C) were treated without () or with (+) lPPase for 30 min and analyzed as in (Figure 1C). The middle shows the differential migration
of HA-p73a.
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p73. Electrophoretic mobility shift assay (EMSA) revealed that
DNA binding of S235D mutant was markedly inhibited, whereas
S235A mutant had weaker DNA-binding ability compared with
WT (Figure 2A). We next evaluated the transactivation function
of p73 phosphor mutants using a p21 promoter-driven luciferase
assay in H1299 cells. S235D mutant had minimal transactivation
of the p21 promoter, whereas S235A mutant had activity similar
to that of WT (Figure 2B). Endogenous p21 protein levels in cells
expressing p73-WT and phosphor mutants were consistent with
the p73 transcriptional activity detected by luciferase assay. p21
levels were low in S235D mutant cells, compared with WT and
S235A mutant cells (Figure 2C). Similarly, p73-S235D mutant
cells demonstrated diminished expression of p73 target genes
Puma, Bax, and Noxa, compared with p73-WT and S235A
mutant cells (Figure 2D).
We determined whether p73 activity depends on Aurora-A
kinase activity and whether S235A mutant is insensitive to this
activity. Luciferase assay revealed that p73-WT activity was in-
hibited by Aurora-A-WT but not by the KD mutant, whereas
S235A mutant was not inhibited by Aurora-A (Figure 2E). Endog-
enous p21 expression levels in these cells were consistent with
the results of luciferase assay (Figure 2F). Similar transactivation
activity and endogenous target gene levels in the WT and S235A
mutant cells appear to be the result of Aurora-A’s inhibitory
phosphorylation interfering with p73-WT’s transactivation func-
tion in vivo. To investigate this, we transfected p73-WT and
S235A mutant in MCF7 cells, which naturally express high levels
of active Aurora-A (Figure 2G). The results revealed distinctly
elevated p21 protein levels in cells expressing S235A mutant
compared with that in cells expressing WT (Figure 2H). Aurora-
A inhibitor treatment of H1299 cells transfected with empty
vector revealed upregulation of p73 target PUMA mRNA,
whereas S235D interfered with transactivation in a dominant-
negative manner (Figure 2I). These results demonstrate that
Aurora-A phosphorylation of p73 at serine 235 negatively regu-
lates p73 transactivation.
Aurora-A Regulates p73 Subcellular Localization
Protein fractionation experiments revealed marked accumula-
tion of S235D mutant in the cytoplasmic fraction, whereas accu-
mulation was predominantly nuclear in the WT and S235A(E) Anti-Flag M2 antibody immunoprecipitates from nocodazole-treated mitotic 2
B-WT, or Flag-Aurora-B-KD were incubated with GST-p73a in the presence of [
ography (left) and Pon-S staining (right). Immunoprecipitated Aurora-A and Auro
(F) Immunoprecipitates with anti-Aurora-A antibody from nocodazole-treated mit
the presence of [g32p]ATP. GST-p73 protein was resolved and visualized as in (F
(G) HA-p73a-WT or -SA were cotransfected with either empty vector or Flag-Au
cipitated with anti-HA antibody, followed by immunoblotting with anti-pPKA subs
with anti-Flag (bottom) antibody. The pPKA signal was normalized by the amoun
(H) GFP-p73a was cotransfected with empty vector or Flag-Aurora-A in 293T
antibody, followed by immunoblotting with indicated antibodies (top and middle
antibody (bottom).
(I) Cos-1 cells were immunoprecipitated with anti-p73 (right) or anti-Aurora-A (
subjected to immunoblotting with anti-p73 and anti-Aurora-A antibodies. Input in
(J) Cos-1 cells were transfected with control siRNA () or p73 siRNA (+) for 48
immunoblotting with anti-p73 (top) and anti-Aurora-A (middle) antibodies, respec
(K) Cos-1 cells synchronized by double thymidine block and release were imm
indicated antibodies.
See also Figure S1.
Cmutant cells (Figure 3A). Similar results were found on immuno-
fluorescence microscopy (Figure 3B) and in different cell lines,
such as HeLa, H1299, and MCF7 (data not shown). We next
analyzed whether the cytoplasmic distribution of S235D mutant
was due to its accelerated export from the nucleus or interfer-
ence with its nuclear translocation by treating cells with leptomy-
cin B, an inhibitor of nuclear export of proteins. Protein fraction-
ations revealed cytoplasmic localization of S235D mutant,
regardless of leptomycin B treatment, and more nuclear
accumulation of WT (Figure 3C), indicating that phosphorylated
p73 at serine 235 is tethered in the cytoplasm. Similar results
were observed for S215D mutant of p53 (Figure S2A). Enrich-
ment of the phosphor-mimetic mutant of p73 in the cytoplasmic
fraction was also observed in nocadazole-arrested mitotic cells
with high Aurora-A activity, possibly coinciding with nuclear
envelope breakdown (Figures S2B and S2C). Because proteins
with aberrant conformations are preferentially transported to
the cytoplasm to be degraded, we determined whether cyto-
plasmic distribution of S235D mutant reflected a conformational
change using a glutaraldehyde-based protein cross-linking
assay. Since p73 is a tetramer in its natural state, and if S235
phosphorylation does not affect monomeric p73 structure,
a slower migrating p73 tetramer would still be detectable on
SDS-PAGE. High-MW S235D and S235A mutants migrated
near the tetrameric form of p73-WT (Figure 3D), indicating that
p73 phosphorylation status at serine 235 does not cause confor-
mational changes.
To determine whether endogenous p73 is distributed in the
cytoplasm with Aurora-A, we performed immunofluorescence
microscopy with anti-p73 antibody. Cells overexpressing
Aurora-A showed evenly diffused endogenous p73 staining in
the cytoplasm and nucleus, which were reversed with Aurora-A
inhibitor (Figures 3E and 3F). Protein fractionation experiments
further confirmed these findings (Figure 3G). p73 is localized in
the cytoplasm of MCF-7 breast cancer cell line and Panc-1
pancreatic cancer cell line, both express elevated Aurora-A
levels (Sen et al., 1997; Li et al., 2003). Inhibitor treatment of
these cell lines resulted in p73 nuclear localization (Figure 3H),
confirming that cytoplasmic distribution of p73 is influenced by
Aurora-A kinase activity. Protein fractionation experiments in
Panc-1 cells also supported this observation (Figure 3I). Similar
results were observed in Aurora-A inhibitor treated MCF-7 cells93T cells transfected with Flag-Aurora-A-WT, Flag-Aurora-A-KD, Flag-Aurora-
g32p]ATP. GST-p73a was resolved by SDS-PAGE and visualized by autoradi-
ra-B were detected with anti-Flag M2 antibody (bottom right).
otic 293T cells were incubated with GST-p73a-WT or GST-p73a-S235A (SA) in
igure 1E).
rora-A-WT into Cos-1 cells. Twenty-four hours later, WCE were immunopre-
trate (top) and anti-HA (middle) antibodies. WCE were directly immunoblotted
t of precipitated HA-p73, and the relative pPKA signal was quantified.
cells. Twenty-four hours later, cells were immunoprecipitated with anti-Flag
). Aliquots of the same cell lysates were directly immunoblotted with anti-GFP
left) antibodies or normal immunoglobulin G (NIG). Immunoprecipitates were
dicates the immunoblot of WCE.
hr and subjected to immunoprecipitation with anti-p73 antibody, followed by
tively. WCE were directly immunoblotted with anti-Aurora-A (bottom) antibody.
unoprecipitated with anti-p73 antibody followed by immunoblotting with the
ancer Cell 21, 196–211, February 14, 2012 ª2012 Elsevier Inc. 199
A D
E
B
C
I
H
G
F
Figure 2. Aurora-A Inhibits DNA Binding and Transactivation Activity of p73
(A) DNA-binding activities of in vitro transcribed and translated proteins of HA-p73a WT, S235A (SA), S235D (SD), and empty vector (emp) were analyzed by
EMSA with a [g32p]ATP-labeled p53/p73 binding consensus oligonucleotide probe. A competition assay was performed with 50-fold molar excess amounts of
unlabeled probe (cold). Buffer was used as a negative control. The reaction was separated by a native polyacrylamide gel (top). The amount of proteins used was
analyzed by immunoblotting with anti-HA antibody (bottom).
(B) H1299 cells were cotransfected with GFP-empty or GFP-p73a-WT or -mutants with luciferase reporter construct containing p21 promoter and Renilla
luciferase reporter internal control plasmid. Twenty-four hours later, cells were subjected to a reporter assay. Data represent mean values ± SD from three
independent experiments.
(C) Protein expression of p21 in cells transfected with GFP-empty and GFP-p73a constructs used in (Figure 2B). Proteins were detected by immunoblotting with
the indicated antibodies.
(D) mRNA expression of p73 target genes in cells used in (Figure 2B), analyzed by semiquantitative RT-PCR.
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phorylation of p73 negatively regulates its nuclear localization.
Mortalin Tethers Phospho-p73 in the Cytoplasm
To identify the proteins bound to phospho-p73, we immunopre-
cipitated protein complexes with WT and S235D mutant of p73.
A protein band of approximately 80 kD MW was detected only
in the immune complex of the S235Dmutant but not theWT (Fig-
ure 4A). Mass spectrometry identified this protein as mortalin,
amember of the hsp70 family that is implicated in immortalization
and tumorigenesis (Deocaris et al., 2007). Gel filtration column
chromatography revealed that p73 and mortalin existed in high-
MW complexes, distributed over a wide size range. It is inter-
esting that theS235Dmutant andmortalin-containing complexes
were significantly more enriched at >2-megadalton-sized frac-
tions than were the p73-WT andmortalin complexes (Figure 4B).
Enrichment of S235Dmutant andmortalin in the highermolecular
complex was also evident in cell extracts resolved on native gels
immunoblotted with anti-p73 and mortalin antibodies (Fig-
ure S3A). We cotransfected WT or deletion mutant of mortalin
(mot del-BD) lacking the p53binding domain (aa 253–282),
described earlier (Ma et al., 2006), with WT or phosphor mutants
of p73 to determine whether mortalin interaction with the S235D
mutant, tethered in the cytoplasm, was mediated through the
same domain involved in p53 binding. WT and mutant p73 did
not interact with themortalin deletionmutant, but full-lengthmor-
talin’s interaction was enhanced with S235D mutant compared
with WT and S235A mutant (Figure 4C). Similar results were
seen in p53 co-immunoprecipitation experiments (Figure S3B).
These results demonstrate that Aurora-A phosphorylation of
p73 and p53 positively regulates their interactions with mortalin,
mediated through the same binding domain.
Immunoprecipitation experiments revealed enhanced interac-
tion of p73 with mortalin in nocodazole-treated mitotic cell
extracts, compared with extracts from exponentially growing
cells, indicating the importance of p73 phosphorylation in
mitosis for mortalin binding. The specificity of this interaction
was verified by immunoprecipitating the extracts from p73
knockdown cells (Figure 4D). The interaction between Aurora-A
and p73 was not affected by mortalin deletion mutant
(Figure S3C).
To further validate the role of Aurora-A phosphorylation in
regulating p73 binding to mortalin, coimmunoprecipitation of
the two proteins was performed with or without Aurora-A inhib-
itor-treated cells transfected with empty vector or Aurora-A
expression vector. Less mortalin bound to p73 in treated cells
than in untreated cells. A similar effect was seen in empty-
vector-transfected cells, reflecting the effects of endogenous
Aurora-A kinase activity on the binding of p73 to mortalin (Fig-
ure 4E). This finding was corroborated in MCF-7 and Panc-1(E) GFP-p73a-WT or -SA mutant was cotransfected with empty vector, Flag-Auro
Data represent mean values with ± SD from three independent experiments.
(F) Protein expression of p21 and transfected GFP-p73a and Flag-Aurora-A in c
antibodies.
(G) Expression analysis of active-Aurora-A (pT288) and total Aurora-A in H1299 a
(H) MCF-7 cells transfected with empty vector, HA-p73a-WT, or -SA mutant for
(I) H1299 cells transfected with empty vector or HA-p73a, cultured without () or w
by semiquantitative RT-PCR.
Ccells (Figure 4F). Ectopic expression of Aurora-A-KD mutant
demonstrated that mortalin protein stability is not affected by
Aurora-A kinase activity (Figure S3D). Decreased binding of
ectopically expressed and endogenous Aurora-A to p73 in inhib-
itor-treated cells verified that the interaction between Aurora-A
and p73 is kinase activity dependent (Figures 4E and 4F).
To determine the effect of mortalin binding on subcellular
localization of phosphor-mimetic p73, S235D mutant was
cotransfected with the mortalin deletion mutant or an empty
vector in Cos-1 cells. In cells with mutant mortalin, the p73
S235D mutant translocated into the nucleus more than in the
empty-vector-transfected cells (Figures 5A and 5B). Protein frac-
tionation experiments also revealed enhanced nuclear accumu-
lation of S235D mutant in mortalin deletion mutant cells than
in control cells (Figure 5C). To determine whether loss of mortalin
expression had a similar effect on p73 localization, S235D
mutant was expressed in cells transfected with control or
mortalin targeting siRNAs. Protein fractionation revealed that
the nuclear:cytoplasmic ratio was relatively higher in mortalin-
siRNA-transfected cells than in control cells, indicating mortalin
involvement in cytoplasmic sequestration of p73 (Figures 5D and
5E). We next analyzed endogenous cytoplasmic p73 in MCF7
and Panc-1 cells after ectopic expression of mortalin deletion
mutant. Nuclear stainingwas detected in 36%ofmortalinmutant
MCF-7 and Panc-1 cells (n = 100) versus 2% of empty vector
cells (Figure 5F). p73 was also enriched in the nuclear fraction
in mortalin mutant cells, whereas it was localized in the cyto-
plasm in empty vector cells (Figure 5G). Aurora-A was also
distributed in the nucleus in mortalin mutant cells, but its nuclear
accumulation was lower than p73 (Figure S4). The microscopy
and fractionation experiments demonstrated a positive correla-
tion between nuclear p73 localization and mutant mortalin
expression. Moreover, mortalin-siRNA-transfected Panc-1 cells
revealed reduced cytoplasmic localization (Figures 5H and 5I)
and phosphorylation of p73 along with increased p21 expression
(Figure 5H and 5J), suggesting that mortalin regulates Aurora-A
phosphorylation of p73 and its transactivation function. Immuno-
precipitation of p73 from empty-vector-transfected cells demon-
strated interaction between p73 and mortalin. This interaction
was weakened in the presence of Aurora-A inhibitor, which
correlated with positive nuclear p73 staining and loss of
Aurora-A interaction with p73. These results point toward an
important role for mortalin in cytoplasmic sequestration of p73
after phosphorylation by Aurora-A.
Aurora-A Phosphorylation of p73 Abrogates Cell Growth
Inhibition and DNA Damage-Induced Cell Death
Response
We determined the physiological effects of Aurora-A phosphor-
ylated p73 on cell growth and DNA damage-induced cell deathra-A-WT, and Flag-Aurora-A-KD in H1299 cells and analyzed as in (Figure 2B).
ells described in (Figure 2E), analyzed by immunoblotting with the indicated
nd MCF-7 cells.
24 hr were analyzed by immunoblotting with the indicated antibodies.
ith (+) Aurora-A inhibitor for 24 hr, and analyzed for mRNA expression of Puma
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Figure 3. Aurora-A Regulates Subcellular Localization of p73
(A) H1299 cells transfected with GFP-p73a expression plasmids for 24 hr were fractionated into cytosolic (Cyto) and nuclear (Nuc) fractions and analyzed by
immunoblotting with anti-GFP antibody. The purity of Cyto and Nuc fractions was confirmed by immunoblotting with anti-a-tubulin and anti-PARP antibodies,
respectively. WCE, whole cell extracts.
(B) H1299 cells transfected with GFP-p73a expression plasmids were analyzed for subcellular localization of GFP fusion p73 by immunofluorescencemicroscopy
and counterstained for DNA with DAPI. Scale bar corresponds to 20 mm.
(C) GFP-p73a-WT or -S235D mutant was transfected into H1299 cells. Twenty-four hours later, cells were further cultured with (+) or without () leptomycin B for
6 hr and subjected to subcellular fractionation as in (Figure 3A).
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Figure 4. Mortalin Interaction with Aurora-A Phos-
phorylated p73
(A) Flag-empty vector (emp), Flag-p73a-WT, or -SD
mutant was transfected into HeLa cells. Twenty-four hours
later, cells were immunoprecipitated with anti-Flag anti-
body conjugated protein-A sepharose and immunopre-
cipitates were eluted with Flag peptide. Eluted proteins
were subjected to SDS-PAGE, and the gel was stained
with Coomassie Brilliant Blue (CBB). Arrow in red shows
mortalin, identified as the p73-interacting protein from this
experiment.
(B) WCE, prepared as in (Figure 4A), were subjected to gel
filtration column chromatography, and an equal volume of
eluted proteins in each fraction was analyzed by immu-
noblotting with the indicated antibodies.
(C) Full-length Flag-mortalin (Full) or p53-binding domain
deletion mutant of Flag-mortalin (del-BD) were co-
transfected with GFP-p73aWT, -SA, or -SD in HeLa
cells. Twenty-four hours later, cells were subjected to
immunoprecipitation with anti-Flag antibody, followed by
immunoblotting with the indicated antibodies (top and
bottom). WCE were directly immunoblotted with anti-GFP
antibody (middle).
(D) Cos-1 cells were transfected with control siRNA ()
or p73 siRNA (+) for 48 hr and grown with or without
nocodazole for 16 hr. Cells were subjected to immuno-
precipitation with anti-p73 antibody, followed by immunoblotting with the indicated antibodies (top and middle). WCE were directly immunoblotted with anti-
mortalin antibody (bottom).
(E) Cos-1 cells were transfectedwith Flag-empty vector () or with Flag-Aurora-A-WT (+).Twenty-four hours later, cells were cultured for 6 hr with (+) or without ()
MLN8054. Cells were then subjected to immunoprecipitation with anti-p73 antibody or normal IgG (NIG), followed by immunoblotting with the indicated anti-
bodies. Input shows immunoblotting of WCE.
(F) MCF-7 and Panc-1 cells were cultured for 6 hr with (+) or without () MLN8054, subjected to immunoprecipitation, and analyzed as in (Figure 4E).
See also Figure S3.
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mutant significantly inhibited colony formation, compared with
S235D mutant (Figure 6A). Because p73 is a critical regulator
of the DNA damage-induced cell death pathway, we determined
whether p73’s phosphorylation status in H1299 cells influenced
cisplatin-induced cell death. Consistent with the expected
induction of proapoptotic genes by p73, cells expressing
WT and S235A mutant showed higher apoptosis than did
the vector-transfected cells, whereas S235D mutant made
cells least sensitive to cisplatin-induced cell death (Figure 6B).
These results demonstrate that Aurora-A phosphorylation
compromises the p73-mediated DNA damage-induced cell
death response. Next, we determined the plausible differential
activation of Aurora-A, p73 phosphorylation, and its nuclear-
cytoplasmic distribution, with or without DNA damage. DNA
damage-inducing cisplatin treatment resulted in loss of Aurora-A
activation and reduced p73 phosphorylation in empty-vector-(D) WCE prepared as in (Figure 3A) were incubated with (+) or without () 0.01
followed by immunoblotting with anti-GFP antibody.
(E) Cos-1 cells were transfected with GFP-empty vector or with GFP-Aurora-AWT
MLN8054 and immunostained with anti-p73 antibody (red). DNAwas counterstain
to 20 mm.
(F) Subcellular distribution of p73 in GFP-positive cells in (Figure 3E) was analyzed
from two independent experiments (n = 100).
(G) Distribution of the proteins in cellular fractions from samples prepared as in (
(H) MCF-7 and Panc-1 cells were incubated with or without MLN8054 for 6 hr an
20 mm.
(I) Protein distribution in cellular fractions from samples prepared in (Figure 3H),
See also Figure S2.
Ctransfected cells, but in the presence of ectopic Aurora-A
overexpression, minimal differences in Aurora-A activation, p73
phosphorylation, and nuclear cytoplasmic distribution were
found between untreated and treated cells (Figure 6C). Empty
vector cells showed elevated nuclear distribution of p73 after
treatment (Figure 6D).
Aurora-A Phosphorylation Inactivates Mitotic SAC
Function of p73
SAC is impaired without p73; thus, we investigated whether
Aurora-A phosphorylation of p73 affects SAC response. We
ectopically expressed mCherry fusion construct of p73 phos-
phor mutants in HeLa cells in which the chromatin was
labeled with stably expressing GFP-tagged histone H2B protein.
Time-lapse microscopy revealed that the duration from nuclear
envelope breakdown to anaphase was shorter in S235D mutant
cells than in controls and S235A mutant cells. S235A mutant% glutaraldehyde for 15 min, and the products were resolved in SDS-PAGE,
. Twenty-four hours later, cells were grown for an additional 6 hr with or without
ed with DAPI (blue). Arrow indicates GFP-positive cells. Scale bar corresponds
and quantified for nuclear and cytoplasmic localization. Mean values ± SD are
Figure 3E), analyzed by immunoblotting with the indicated antibodies.
d subjected to immunostaining as described in (E). Scale bar corresponds to
analyzed by immunoblotting with the indicated antibodies.
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Figure 5. Mortalin Interaction Regulates Cytoplasmic Distribution of p73
(A) HA-p73a-SD was cotransfected with GFP-empty vector or GFP-mortalin-del-BD into Cos-1 cells. Twenty-four hours later, cells were immunostained with
anti-HA antibody (red) and counterstained for DNAwith DAPI (blue). Arrow showsGFP-positive cells with nuclear staining of HA-p73a-SD. Scale bar corresponds
to 20 mm.
(B) Subcellular distribution of HAp73a SD in GFP-positive Cos-1 cells prepared as in (Figure 5A) was analyzed and quantified. Mean values ± SD are from three
independent experiments (n = 100).
(C) Cos-1 cells prepared as in (Figure 5A) were fractionated into cytosolic (Cyto) and nuclear (Nuc) fractions and analyzed by immunoblotting with anti-HA and
anti-Flag antibodies. The purity of Cyto and Nuc fractions was confirmed by immunoblotting for anti-a-tubulin and anti-PARP antibodies, respectively.
(D) Cos-1 cells were transfected with control siRNA () or mortalin siRNA (+) for 48 hr and subjected to immunoblotting with anti-mortalin (top) and anti-b-actin
(bottom) antibodies, respectively.
(E) Cos-1 cells transfected with control or mortalin siRNA for 24 hr were transfected with GFP-p73a-SD. Twenty-four hours later, cells were subjected to
fractionations, followed by immunoblotting, as in (Figure 5C).
(F) MCF-7 and Panc-1 cells were transfected with GFP-mortalin-del-BD for 24 hr, immunostained with anti-p73 antibody (red), and counterstained for DNA with
DAPI (blue). Arrow indicates GFP-positive cells. Scale bar corresponds to 20 mm.
(G) Panc-1 cells were transfected with Flag-empty vector or Flag-mortalin-del-BD. Twenty-four hours later, cells were subjected to fractionation, followed by
immunoblotting as in (Figure 5C).
(H) Panc-1 cells were transfected with control siRNA () or mortalin siRNA (+) for 48 hr and subjected to immunoblotting with anti-mortalin (top) and anti-b-actin
(bottom) antibodies, respectively.
(I) Panc-1 cells prepared in (Figure 5H) were subjected to fractionations, followed by immunoblotting as in (Figure 5C).
(J) WCE prepared in (Figure 5H) were immunoprecipitated with anti-p73 antibody, followed by immunoblotting with the indicated antibodies (top and second).
WCE were directly immunoblotted with the indicated antibodies also (third and bottom).
See also Figure S4.
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Figure 6. Role of Phospho-p73 Mutant in Cell Growth and Response to DNA Damage-Induced Cell Death
(A) Colony formation assay in SAOS-2 cells grown for 3 weeks under G418 selection after transfection with the indicated p73 expression constructs. Repre-
sentative photos of culture plates from one experiment are shown (top). Mean colony numbers ± SD from three independent experiments are shown in the graphs
(bottom).
(B) H1299 cells were transfected with the indicated expression constructs. Twenty-four hours later, untreated cells () and cells treated with cisplatin (+) for 24 or
36 hr were subjected to annexin-V assay. The graph represents the mean annexin-V-positive apoptotic cells ± SD from two independent experiments.
(C) Flag-empty vector or Flag-Aurora-A cells, transfected for 24 hr, were treated with cisplatin (50 mM) for 6 hr. Cells were subjected to immunoprecipitation with
anti-p73 antibody, followed by immunoblotting with the indicated antibodies (top and second). WCE were directly immunoblotted with antibodies, as shown.
(D) Cells prepared as in (C) were subjected to fractionations, followed by immunoblotting with the indicated antibodies.
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Aurora-A Regulation of p73 Checkpoint Functioncells took the longer to transition into anaphase (Figure 7A).
S235D mutant cells had no abnormal chromosome alignment
but had frequent chromosome bridges in anaphase-telophase
cells, reflecting defects in the chromosome segregation process.
To determine whether this resulted from aberrant SAC function,
we grew cells expressing p73 phosphor mutants, with or without
nocodazole, and quantified them in terms of mono- and multinu-
cleation, presence in mitosis, or apoptosis induction (Figure 7B).
Nocodazole treatment of empty vector and S235A mutant cellsChad similar effects, with 48.8 ± 1.9% and 46.2 ± 0.4%, respec-
tively, in mitosis and 14 ± 2.4% and 19.4 ± 1.4%, respectively,
displaying multinucleation. In contrast, nocodazole treatment
resulted in fewer S235D mutant cells in mitosis (31.3 ± 1.3%)
andmore multinucleation (41 ± 2.2%). Increasedmultinucleation
was also seen in untreated S235D mutant cells, compared with
untreated empty vector and S235Amutant cells (Figure 7B), indi-
cating that Aurora-A phosphorylation of p73 has a role in inacti-
vating the SAC response. Furthermore, p73 phosphor cells wereancer Cell 21, 196–211, February 14, 2012 ª2012 Elsevier Inc. 205
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Figure 7. Effects of Aurora-A Phosphorylated p73 on Mitosis and SAC Complex
(A) HeLa/GFP-H2B cells were transfected with mCherry-p73a-SA or -SD mutant. Twenty-four hours later, cells were monitored by time-lapse microscopy using
a low level of light intensity to determine the duration from nuclear envelope breakdown to anaphase. Mock-transfected cells were used as the control. The table
represents mean mitotic durations ± SD and percentages of cells with defects in chromosome segregation or separation (top). Selected still frames from time-
lapse microscopy of transfected cells at time intervals of minutes and seconds are shown (bottom). Scale bar corresponds to 10 mm.
(B) HeLa/GFP-H2B cells transfected with mCherry-empty vector, p73a-SA, or -SD mutant for 24 hr were cultured with (w Noc) or without (w/o Noc)
nocodazole. Eighteen hours later, cells were fixed, and the fate of mCherry-positive cells was analyzed by fluorescence microscopy and quantified. The
percentage values of cells in mitosis, with the indicated nuclear phenotypes from three independent experiments (n = 200), are shown. Scale bar corresponds
to 10 mm.
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inhibitor that blocks E3 ubiquitin ligase anaphase-promoting
complex/cyclosome (APC/C) involved in cyclin B1 degradation.
Cyclin B1 levels in S235D mutant cells were lower than in empty
vector and S235A mutant cells without MG132 but with MG132,
cyclin B1 levels were similar in these cells, demonstrating that
S235D mutant expression impairs nocodazole-induced mitotic
arrest (Figure 7C). Nocodazole-treated p73-knockdown cells,
however, had reduced cyclin B1 levels, compared with levels
in control cells (Figure S5A).
We next investigated whether Aurora-A phosphorylation of
p73 is a normal physiological event in cells with basal Aurora-A
expression or an unnatural event in Aurora-A-overexpressing
tumor cells. For the purpose, Aurora-A phosphorylation of
p73 was evaluated in synchronized MCF-10A and Cos-1 at
prophase; metaphase and anaphase stages. Western blotting
of immunoprecipitated p73 with anti-phospho-PKA substrate
antibody revealed that p73 phosphorylation progressively
peaked at metaphase but was barely detectable in anaphase,
when both amount and activity of Aurora-A were significantly
reduced (Figure S5B). These findings indicate that Aurora-A
phosphorylation of p73 has a role in regulating SAC during
normal mitosis in cells with basal Aurora-A expression. It
is conceivable that elevated Aurora-A expression weakens
the SAC due to precocious phosphorylation of p73 in tumor
cells. Interestingly, co-transfection of S235D mutant with
mortalin siRNA failed to override mitotic arrest, as evident
from the similar expression levels of cyclin B1 in control and
mortalin siRNA transfected cells (Figure 7D), suggesting that
silencing of mortalin can rescue phosphor-p73-mediated SAC
inactivation.
Coimmunoprecipitation with anti-p73 and anti-CDC20 anti-
bodies revealed complex formation of p73 with Mad2, CDC20,
and Aurora-A (Figure 7E). Thus, we determined the effect of
p73-S235D mutant expression on these protein-protein interac-
tions in cells treated with nocodazole and MG132. Coimmuno-
precipitation experiments with anti-CDC20 antibody revealed
a marked reduction in the interaction of both S235D mutant
and MAD2 with CDC20, compared with that in empty vector
and S235A mutant cells, whereas BubR1’s interaction with
CDC20 was not affected in S235D mutant cells (Figure 7F;
data not shown). Immunoprecipitation with BubR1 and MAD2
antibodies did not reveal the two proteins in the same complex
from nocodazole-treated cell extracts (data not shown), indi-
cating that the two checkpoint proteins form independent
complexes with CDC20, as reported earlier (Fang, 2002). Immu-
nofluorescence microscopy revealed that kinetochore-localized
Mad2 is not affected by ectopic expression of S235D mutant(C) 293T cells transfected for 24 hr with GFP-empty vector, p73a-WT, -SA, or -SD
with (+) or without () MG132 for 4 hr and subjected to immunoblotting with the
(D) HeLa/GFP-H2B cells transfected with control or mortalin siRNA for 24 hr
constructs. Twelve hours later, cells were cultured with nocodazole for 18 hr and
(E) WCE from nocodazole-treated 293T cells were immunoprecipitated with norm
subjected to immunoblotting with the indicated antibodies.
(F) 293T cells transfected with the indicated expression constructs for 24 hr we
subjected to immunoprecipitation with normal IgG (NIG) or anti-CDC20 antibody
(G) Saos-2 cells were transfected with the GFP-empty vector or GFP-p73a-SD m
Mad2 antibody (red) and counterstained for DNA with DAPI (blue). Scale bar cor
See also Figure S5.
C(Figure 7G). These results demonstrate that p73 is involved in
the formation of a cytoplasmic ternary complex with MAD2
and CDC20. Aurora-A phosphorylation of p73 in this complex
releases p73 and the inhibitory complex between MAD2 and
CDC20, with the released CDC20 expected to facilitate activa-
tion of APC/C, leading to mitotic exit.
Aurora-A Overexpressing Primary Pancreatic Cancer
Shows High Cytoplasmic p73 Distribution
To determine whether cytoplasmic sequestration of p73, conse-
quent to Aurora-A phosphorylation, is reflected in cytoplasmic
p73 distribution in Aurora-A-overexpressing tumors, we per-
formed immunohistochemical analyses of p73 and Aurora-A in
two sets of primary human pancreatic cancer tissues—114
pancreatic ductal adenocarcinoma (PDAC) samples from M.D.
Anderson and 20 from the University of Alabama at Birmingham
(UAB). p53 localization was also determined because Aurora-A
phosphor-mimetic p53-S215D mutant demonstrated cyto-
plasmic localization and preferential interaction with mortalin
(Figures S2A and S3B). Fifty-one (44.7%) PDAC samples
showed high Aurora-A expression. Cytoplasmic p73 staining
was clearly detected, but positive cytoplasmic p53 staining
was almost undetectable. Among 51 tumors, 37 (72.5%) had
high cytoplasmic staining of p73 and 22 (43%) had nuclear stain-
ing of p53. Among the remaining 63 Aurora-A low tumors, only 18
(28.6%) had strong cytoplasmic p73 staining and 40 (63%) had
nuclear p53 staining (Figure 8). These results reveal a relationship
between Aurora-A expression and cytoplasmic p73 localization
and between Aurora-A expression and nuclear p53 localization
in primary PDAC tissue. A similar trend between Aurora-A
expression and p73 distribution was also found in the UABCC
tissue set (data not shown). Nuclear localized mutant p53 is
reported in 50%–75% of PDAC; thus, the predominant p53
nuclear distribution was not unexpected. The relationship
between high Aurora-A expression and low p53 nuclear staining
suggests that Aurora-A overexpression is correlated with p53
gene mutations in PDAC, whereas p53-WT remains undetect-
able in the cytoplasm, possibly because of enhanced protein
degradation after Aurora-A phosphorylation, as previously
described (Katayama et al., 2004; Morton et al., 2010).
DISCUSSION
Aurora-A overexpression is detected in various tumor types and
confers resistance to chemotherapeutic drugs and irradiation
(Zhou et al., 1998; Marumoto et al., 2002; Yang et al., 2006).
We present evidence that the p73 tumor suppressor protein is
a direct downstream target of Aurora-A, which influences cellmutant were cultured with nocodazole. Sixteen hours later, cells were grown
indicated antibodies.
were subsequently transfected with HA-p73a-SA or -SD mutant expression
subjected to immunoblotting with the indicated antibodies.
al IgG (NIG) or with anti-p73 or anti-CDC20 antibody. Immunoprecipitates were
re incubated with nocodazole for 20 hr and then MG132 for 4 hr. Cells were
, followed by immunoblotting with the indicated antibodies.
utant construct. Twenty-four hours later, cells were immunostained with anti-
responds to 10 mm.
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Figure 8. Correlation of Aurora-A Expression Levels with p73 and p53 Localization in Human PDAC
(A) Representative micrographs of PDAC tissues with varying levels of Aurora-A, p73, and p53 expression. Scale bar corresponds to 50 mm.
(B and C) Bar graph representation of relative cytoplasmic p73 expression and nuclear p53 expression in relation to high or low Aurora-A expression in the tissue
microarray containing 114 PDAC tissue samples. Aurora-A expression was correlated significantly with cytoplasmic p73 expression (p < 0.0001). Nuclear p53
staining showed a trend towards being inversely corerlated with the levels of Aurora-A expression in these PDAC tissue samples.
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damage in tumor cells. Aurora-A phosphorylation of p73 at
serine 235 is critical in Aurora-A overexpression-mediated abro-
gation of apoptotic response and mitotic checkpoint override.
Aurora-A Inhibits p73 and p53 Transactivation
Functions through a Common Molecular Mechanism
We, as well as others, have reported that Aurora-A phosphoryla-
tion of p53 compromises its apoptosis response function
induced after cisplatin and irradiation treatment, whereas
Aurora-A knockdown sensitizes cells to DNA damage-induced
p53-dependent apoptosis (Katayama et al., 2004; Liu et al.,
2004). The current findings reveal that Aurora-A phosphoryla-
tions abrogate DNA damage response functions of both p53
and p73 consequent to their interactions with mortalin and cyto-
plasmic sequestration. It also appears that, with progressively
increasing Aurora-A kinase activity during mitosis, p53 and p73
remain localized in the cytoplasm coincidentally with nuclear
envelope breakdown. Phosphorylation-mediated binding to
mortalin, promoting nuclear exclusion of p53 and p73, may be
common in tumor cells (Walker et al., 2006; Walker and Bo¨ttger,208 Cancer Cell 21, 196–211, February 14, 2012 ª2012 Elsevier Inc.2008) and consistent with the earlier observations that p53-
binding domain on mortalin (Kaul et al., 2001) negatively regu-
lates transcriptional activity, inhibits nuclear translocation of
p53, and abolishes p53-dependent suppression of centrosome
duplication (Wadhwa et al., 1998; Walker et al., 2006; Ma et al.,
2006). Because the mortalin-binding domain of p53 at its C
terminus (Kaul et al., 2001;Wadhwa et al., 2002) is not conserved
in p73, it is worth investigating whether Aurora-A phosphoryla-
tion of p53 and p73 creates a mortalin-binding site or recruits
a mortalin interaction factor in a phosphorylation-dependent
manner. Complex formation between mortalin and p53 has
been detected in the mitochondria during p53-induced
apoptosis, with and without DNA damage (Marchenko et al.,
2000), implicating involvement of mortalin-p53 complex in the
transactivation-independent apoptotic signaling pathway. How-
ever, the molecular mechanisms regulating activation of this
pathway remains to be elucidated. WWOX, a putative tumor
suppressor protein, interacts with p53 and p73, regulating
their subcellular distribution and apoptosis response functions
elicited in mitochondria (Chang et al., 2003; Chang et al., 2005;
Aqeilan et al., 2004). On the basis of the current findings, it
Cancer Cell
Aurora-A Regulation of p73 Checkpoint Functionmay be suggested that Aurora-A phosphorylation-induced mor-
talin binding influences interactions of p53 and p73 with WWOX
and/or proapoptotic mitochondria proteins. Further investigation
is needed to understand these pathways.
Molecular Mechanism of Aurora-A-Mediated
Inactivation of Mitotic SAC Function of p73
Aurora-A overexpression has been shown to override mitotic
SAC and induce aberrant chromosome segregation, resulting
in aneuploidy (Anand et al., 2003). However, the underlying
molecular mechanism of this effect has remained unclear. We
found that p73 was involved in the inhibitory mitotic checkpoint
complex of Mad2 and CDC20, preventing activation of the E3
ubiquitin ligase APC/C, and that Aurora-A phosphorylation of
p73 caused dissociation of the Mad2-CDC20 complex, facili-
tating mitotic exit. Because p73 is detected in large macromo-
lecular complexes including mortalin, further studies are needed
to determine their functional significance in the regulation of the
Mad2-CDC20 containing SAC complex.
We observed no specific localization of WT or phosphor-
mimetic p73 mutants at the mitotic apparatuses or an effect of
phosphor-mimetic mutant on Mad2 mislocalizations at the
kinetochore. However, immunostaining with anti-p73 antibody
revealedcytoplasmic andmitotic spindle p73 localization.Mitotic
SACgenerates a diffusible wait signal atmicrotubule-unattached
kinetochores that inhibits CDC20-mediated APC activation.
MAD2 and BubR1 are the two most critical proteins of this signal
(Shah et al., 2004; Peters, 2006), which form separate inactive
complexes with CDC20 (Fang, 2002). Although evidence sug-
gests that the soluble MAD2-CDC20 complex acts as a transient
precursor to the BubR1-CDC20 inhibitory complex (Kulukian
et al., 2009), the exact mechanism is still not well understood.
Failure of BubR1 to rescue SAC dysfunction in cells expressing
a mutant CDC20 allele that does not bind MAD2 (Li et al., 2009)
clearly illustrates a critical, nonredundant role of Mad2 in SAC
activation. Aurora-A phosphorylation of p73 dissociated the
MAD2-CDC20 complex, providing evidence that Aurora-A nega-
tively regulates a critical step in the SAC activation pathway.
Unlike its effect on Mad2-CDC20 interaction, phosphor-mimetic
mutant p73 did not affect the interaction of BubR1 with CDC20.
Progressively increasing Aurora-A phosphorylation of p73 from
prophase through metaphase, followed by a sharp decline at
anaphase and telophase in synchronized nontumorigenic MCF-
10A cells, with basal Aurora-A expression, suggests that this
phosphorylation has a role in inactivating SAC during the meta-
phase–anaphase transition of normal mitosis. Constitutively
phosphorylated p73-expressing cells underwent an early transi-
tion to anaphase and overrode the mitotic checkpoint, indicating
that Aurora-A-overexpressing cells are predisposed to abrogate
the checkpoint response because of precocious p73 phosphor-
ylation. Our findings do not reveal how this phosphorylation is
temporally regulated to coincidewith SAC inactivation after chro-
mosome biorientation in normal mitosis. Structural studies have
revealed that an open conformation of MAD2 prevents associa-
tion with MAD1 or CDC20 (Musacchio and Hardwick, 2002).
Thus, it will be interesting to determine whether Mad2-bound
p73 phosphorylation induces open conformation changes in
the latter, leading to its dissociation from CDC20. Our findings
indicate that p73 is a critical regulator of the cytoplasmicCMAD2-CDC20 checkpoint protein complex. Additional studies
are required to unravel the details of thesemolecular interactions.
p73-deficient mice have a high incidence of spontaneous
tumors (Tomasini et al., 2008) and loss of function is correlated
with induction of chromosomal instability (Talos et al., 2007).
Evidence supports a role for p73 in mitosis (Fulco et al., 2003;
Merlo et al., 2005), including SAC regulation (Tomasini et al.,
2009). Thus, p73 plays an important role in faithful chromosome
segregation and maintenance of genomic stability. p73 is upre-
gulated during the transformation process in response to aber-
rant Rb pathway expression, and a genetic alteration with a
dominant negative effect is required to block tumor suppressor
function of p73. Published data indicate that overexpression of
the dominant negative p73 protein DNp73 compromises tumor
suppressor function of p73 in premalignant stages (Oswald and
Stiewe, 2008).DNp73 overexpressionmay disrupt the stochastic
balance of Aurora-A-mediated p73 SAC function because the
two isoforms, despite forming a heterotetramer, do not share
the predominant site of Aurora-A phosphorylation in p73.
Our findings demonstrate that elevated Aurora-A expression,
a common oncogenic event in human cancers, has the dominant
negative effect of inactivating p73 function through increased
phosphorylation of the protein sequestered in the cytoplasm.
The positive correlation between Aurora-A overexpression and
cytoplasmic p73 localization in human pancreatic cancer
tissue corroborate the experimental findings and indicates that
these tumors have weakened or inactivated DNA and spindle
damage-induced apoptosis and SAC pathways, making them
refractory to conventional radiation and chemotherapeutic regi-
mens. Detailed analyses of p73 phosphorylation profiles of these
tumors together with chemosensitivities and radiosensitivities
would help resolve the issue and future design of appropriately
targeted therapies.
In conclusion, we uncovered a signaling pathway of Aurora-A-
p73 axis in which Aurora-A phosphorylation inactivates p73
function in both DNA damage-induced cell death and mitotic
SAC pathways. Further in-depth studies of Aurora-A involve-
ment in both signaling pathways will improve our understanding
of oncogenic function of Aurora-A in cancer biology and help us
develop more effective strategies for cancer prevention and
treatment.
EXPERIMENTAL PROCEDURES
All cell lines were obtained from ATCC. Immunohistochemical staining for
Aurora-A, p73, and p53 was performed on 4-mm unstained sections from
tissue microarray blocks consisting of 114 PDAC and 20 pancreatic tumor
tissues from patients who had undergone pancreaticoduodenectomy at
M.D. Anderson and UAB, respectively. The studies were approved by both
institutional review boards.
Detailed experimental procedures are available in the Supplemental Exper-
imental Procedures.
Transfection, Luciferase Assay, and siRNA
For transfection, Fugene 6 transfection reagent (Roche), oligofectamine, and
lipofectamine 2000 (Invitrogen) were used according to manufacturer’s
instructions. For luciferase assays, H1299 or Saos-2 cells were cotransfected
with the same amount of WT or mutant pEGFPp73a (100–200 ng), luciferase
reporter construct (100 ng), and internal control Renilla luciferase expression
plasmid (10 ng), with or without increasing amounts of Flag-Aurora-A WT
or KD expression plasmids. The total amount of plasmid DNA was keptancer Cell 21, 196–211, February 14, 2012 ª2012 Elsevier Inc. 209
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transfection using a dual-luciferase reporter assay kit (Promega). The siRNA
sequences were as follows: p73, 50-CGGAUUCCAGCAUGGACGUdTdT-30
(Basu et al., 2003); mortalin, 50-CCGUCUCGUGGGCGCCGCAdTdT-30
(Ma et al., 2006). Additional siRNAs for both genes from Santa-Cruz
Biotechnology (Catalog Nos. sc-35520 for mortalin and sc-36167 for p73)
were also used.
Cell Fractionation, Cross-Linking Assay, In Vitro Kinase Assay,
Semiquantitative RT-PCR, Immunoprecipitation, Western Blotting,
and Immunofluorescence Microscopy
Biochemical protein fractionation of cells was performed according to the
manufacturer’s protocol (Pierce). Whole cell extracts were prepared in RIPA
buffer. All other experimental procedures, conditions, and primer sequences
for semiquantitative RT-PCR have been described (Kawai et al., 2007;
Katayama et al., 2007, 2008; Li et al., 2007).
EMSA
p73 proteins, produced by an in vitro transcription and translation kit
(Promega), were incubated with 32P-labeled p21 probe containing the p53
DNA-binding site (50-TACAGAACATGTCTAAGCATGCTGGGG-30 ) in the bind-
ing buffer (20 mM HEPES, pH 7.9, 1 mM MgCl2, 10 mM ZnCl2, 1 mM DTT, 5%
glycerol, 670 ng/ml BSA, and 0.5 mg/ml poly(dI-dC) at room temperature for
20 min. For the competition assay, 1 mg of unlabeled probe was added to
the reaction. The protein-DNA complexes were resolved by electrophoresis
through 4.5% polyacrylamide gel at 4C.
lPPase Treatment
Whole cell extracts were incubated with 20 units of lPPase (New England Bio-
labs) or glycerol (solvent) in the supplemented buffer for 30 min at 30C. The
reaction was terminated by adding SDS sample buffer and subjected to
SDS-PAGE.
Gel Filtration Column Chromatography
Gel filtration column chromatography was carried out as described previously
(Samanta et al., 2010). In brief, 3 mg of whole cell extracts prepared in column
elution buffer (30 mMHEPES, pH 7.4, containing 150 mMNaCl and 10% glyc-
erol, and 0.5%NP-40, 1mMmicrocystin LR, protease inhibitor cocktail [Roche])
were loaded on the columnpackedwith Superose 6 prep grade gel (GEHealth-
care), and 500 ml of elution was collected in each fraction. Equal volumes of
eluted fractions were subjected to immunoblotting. The mixture of protein
markers containing keyhole limpet hemocyanin (KLH; MW 8.5 million Da),
blue dextran (MW 2 million Da), b-amylase (MW 200 kDa), BSA (MW 66 kDa),
and cytochrome C (MW 12.4 kDa) was used as the MW standard.
Time-Lapse Microscopy
We performed time-lapse microscopy using a Perkin Elmer UltraVIEW ERS
spinning disc confocal microscope equipped with an environmental control
chamber that maintained the cells at 37C in a humidified stream of 5%
CO2. Individually tagged image format files were imported into Photoshop
(Adobe) for analysis.
Colony Formation Assay and Drug Treatment
Saos-2 cells (transfected with pEGFP-empty vector, WT, and mutants of
pEGFP-p73a) were cultured inmedia containing 200 mg/ml ofG418 for 3weeks
and stained with crystal violet. Colonies of 1 mm diameter were counted.
H1299 cells transfected for 24 hr were treated with cisplatin at 50 mM for
24 hr and 36 hr. Annexin V-FITC assay was performed according to the manu-
facturer’s protocol (BD PharMingen). Nocodazole was used at 50 ng/ml for
GFP-H2B HeLa, 350 ng/ml for 293T, 500 ng/ml for MCF-7 and Panc-1, and
1 mg/ml for Cos-1 cells. Aurora-A inhibitor MLN8054 was used at 0.5 mM
with or without 20 mM of MG132 for 4–6 hr.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
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